Doctors Without Borders: AIDS Drug Discounts Threatened - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Doctors Without Borders: AIDS Drug Discounts Threatened



According to a price report by Medecins Sans Frontieres (MSF, or Doctors Without Borders) released July 18, 2011, several pharmaceutical companies have withdrawn drug price reductions in middle-income countries, such as India, Indonesia, Thailand, Vietnam, Ukraine, Colombia and Brazil.

“While there is continued progress to reduce prices for the poorest countries, a significant number of people with HIV/AIDS live in countries that are now excluded from price reductions,” said Nathan Ford, medical director of MSF’s Campaign for Access to Affordable Medicines, according to a press statement.

MSF started HIV treatments in Asia and Latin America over ten years ago, but handed responsibility over to local authorities on the assumption that people would gain access to treatment from government programmes. However, the drug company discount programmes do not apply to newer drugs. According to Janice Lee, HIV/AIDS pharmacist at MSF’s Campaign for Access to Essential Medicines, “When patents get in the way and drug companies refuse to cut prices, governments are going to have to start overriding patents so that they can afford to keep their HIV-positive people alive.”

The MSF price report also contains good news: once a day formulations containing tenofir have seen a 70% reduction in price due to generic competition allowing a move to a WHO-recommended, less toxic treatment.

Nevertheless, patents continue to be a barrier to reduced pricing across the board, and that could hinder the UN goal of providing universal access to antiretroviral therapy to all people living with HIV who are eligible for treatment.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here